Latest News-CSTONE PHARMACEUTICALS Mediaroom_Page

CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022

* Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical st...

2022-04-28 08:00 3247

CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published in the New England Journal of Medicine

* Results from the trial present a significant advancement for patients dealing with previously u...

2022-04-22 08:02 3971

CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American Association for Cancer Research (AACR) Annual Meeting 2022

* Results from pharmacokinetic/pharmacodynamic modeling demonstrated that binding affinity optimi...

2022-04-13 08:02 2838

CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC

* Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CSt...

2022-03-31 08:02 3756

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a lead...

2022-03-18 10:35 3571

CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcinoma successfully reached the prespecified enrollment target

SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a lead...

2022-03-18 08:37 3826

CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer

* GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved...

2022-03-14 08:05 3881

CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancers in Taiwan, China

SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2022-02-17 09:19 4738

CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia

* TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute ...

2022-02-09 11:53 4492

CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients

* Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with ch...

2022-01-19 08:05 3657

CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment

* Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in pat...

2022-01-18 08:00 4445

CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology

SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2022-01-15 08:35 6165

CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology

SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2022-01-15 08:31 5572

CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)

* Sugemalimab has the potential to become the world's first immunotherapy to be approved for pati...

2022-01-13 08:05 6985

CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration

SUZHOU, China, Jan. 3, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadin...

2022-01-03 08:00 4387

CStone announced new drug approval of precision therapy AYVAKIT® (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST)

* AYVAKIT is the first precision therapy approved in Hong Kong, China for the treatment of patien...

2021-12-28 08:00 4138

CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER

SUZHOU, China, Dec. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals (the " Company" or "CStone") is ...

2021-12-21 16:56 3896

Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia

* TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated ...

2021-12-12 09:00 6201

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2021-11-21 17:09 3717

CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China

SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leadi...

2021-11-21 17:02 3345